First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

NCT04391283 · clinicaltrials.gov ↗

UNKNOWN

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Osimertinib

Sponsor

First Affiliated Hospital of Zhejiang University

Collaborators

[object Object]